← All Sponsors
SPONSOR

Qingdao Central Hospital

Total Trials
2
Recruiting
2
Phases
Phase 2, Phase 3
Conditions studied: EGFR Positive Non-small Cell Lung CancerMET AmplificationNutrition DisordersImmunotherapyCancerSurvival, Prosthesis
NCT07322783 Phase 2
Recruiting

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

EGFR Positive Non-small Cell Lung Cancer
China View Trial →
NCT06500234 Phase 3
Recruiting

Nutrition Impact on Immunotherapy of Cancer

Nutrition Disorders
China View Trial →